[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Maastricht Radiation Oncology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":291},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,37,81,105,130,153,177,200,218,242,262],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100463632","developing-breast-cancer-organoids-100463632",false,"NCT05317221","Developing Breast (Cancer) Organoids","Inclusion Criteria:\n\n* Female,\n* \\>18 years,\n* Family Anamneses\n* Breast cancer (proven by histopathology), Included subtypes; (ER-,PR- HER2-); (ER+, PR+, HER2-); (ER+, PR+ HER2+).\n* Primary surgery (lumpectomy or mastectomy)\n\nExclusion Criteria:\n\n\\- Physically or mentally incapable or incompetent to sign informed consent","FEMALE","18 Years",{"count":18,"type":19},60,"ESTIMATED","OBSERVATIONAL","Currently, only a few validated biomarkers and models exist guiding or predicting treatment response for specific patient groups. Therefore, a patient-tailored clinical model needs to be developed to address tumour heterogeneity and thereby guide treatment selection on an individualized level. Organoids are patient-derived aggregates that grow in 3D and maintain self- renewal pluripotency and lineage-specific differentiation. Therefore, in contrast with conventional cell lines, they are thought to sustain patient heterogeneity and characteristics and are consequently already in use for drug response screening.\n\nThis now offers the opportunity to investigate if the primary patient breast cancer organoid platform reflects disease progression, treatment response and relapse in patients with different clinical breast cancer subtypes.\n\nGoal: To develop a living biobank from prospective patient-derived breast cancer tissue. The questions we will address are:\n\n1. Do patient-derived breast cancer organoids retain the clinical behaviour and characteristics of the primary patient tumour?\n2. Can BC organoids be used to derive prognostic and predictive biomarkers to inform treatment decisions?\n3. Can the investigators utilize BC organoids to discover novel actionable targets and combination treatments for therapeutic intervention for breast cancer patients?\n4. Can BC organoids be used to discover mechanisms of treatment resistance and relapse?",[23],"Breast Cancer","RECRUITING","2026-05-07",{"date":27,"type":28},"2026-05-12","ACTUAL",{"date":30,"type":28},"2022-09-01",{"date":32,"type":19},"2028-05-01",{"name":34,"class":35},"Maastricht Radiation Oncology","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":45,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":54,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100593295","lab-research-using-mini-tumors-to-study-prostate-cancer-treatments-100593295","NCT07004582","Lab Research Using Mini-tumors to Study Prostate Cancer Treatments","Preclinical ex Vivo Patient-derived 3D Cultures for the Prediction of Prostate Cancer Treatment Response","PR3DICT","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* Patients with prostate cancer\n* Patients planned for HDR brachytherapy treatment for high-risk or recurrent prostate cancer or transperineal prostate biopsy with MRI-suspected metastatic prostate cancer with at least clinical stage T3-4.\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Patients of whom it is not possible to obtain left-over tissue as part of the normal clinical treatment procedure (e.g., if all tumor material is required for the pathologist to make a diagnosis, to stage the patient or to perform a molecular diagnosis).","MALE",{"count":47,"type":19},600,"For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer.\n\nIn the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.",[50,51,52,53],"Prostate Cancer","Prostate Cancer Metastatic Disease","Prostate Cancer Recurrent","Advanced Prostate Cancer",[55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71],"Advanced prostate cancer","Metastatic prostate cancer","Prostate cancer","Patient-tailored treatment","Precision Medicine","Ex vivo prediction platform","Personalized medicine","Drug Screening Assays","Three-Dimensional Culture Techniques","Organoids","Tumoroids","Tumor replicas","Prostatic Neoplasms","Neoplasm Metastasis","Advanced Cancer","Treatment Outcome","Human Tissue Culture Techniques","2026-04-20",{"date":74,"type":28},"2026-04-23",{"date":76,"type":28},"2026-03-15",{"date":78,"type":19},"2031-12-30",{"name":34,"class":35},3,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":36},"100631527","registry-maastro-applicator-100631527","NCT07501845","Registry Maastro Applicator","Prospective Data Collection Initiative on MAASTRO HDR Rectal Applicator Treatments - a Prospective Observational Cohort Study.","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histological proof of rectal cancer, or a strong suspicion after imaging.\n* Treatment with MAASTRO HDR rectal applicator\n* Informed consent for longitudinal observational data collection.\n\nExclusion Criteria:\n\n* Mentally incompetent patients.","ALL",{"count":90,"type":19},999,"This registry will collect data from all patients treated with the MAASTRO HDR applicator. The goal is to deepen knowledge about dose-response relationships in rectal cancer boosting, which is essential for improving future treatment approaches and patient selection.",[93],"Rectal Cancer",[95,96],"rectal cancer","HDR Brachy","2026-04-08",{"date":99,"type":28},"2026-04-13",{"date":101,"type":28},"2026-03-23",{"date":103,"type":19},"2034-12-31",{"name":34,"class":35},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":36},"100428919","a-living-tissue-bank-of-patient-derived-organoids-from-glioma-tumors-100428919","NCT04865315","A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors","HiLoGlio Organoid Study: 'A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors'","HiLoGlio","Inclusion Criteria:\n\n* MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)\n* Age 18 years or older\n* Patient is eligible for a resection of the tumor\n\nExclusion Criteria:\n\n* Contra-inidication for neurosurgical resection of the tumor.\n* Incapacitated patient, unable to give informed consent.",{"count":114,"type":19},50,"There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available. To achieve this goal, a broader understanding is needed of the causes of inter-and intratumoral heterogeneity; glioma dedifferentiation and invasion; the major determinants of malignancy and treatment failure in glioma patients. Patient-derived organoid (PDOs) of high-grade gliomas and low-grade gliomas will be used to identify the mechanisms that underlie this malignant behaviour and treatment resistance. This insight may be used to develop patient avatars to simultaneously test multiple new treatment modalities that are predictive for survival and quality of life of glioma patients.",[117,118],"Low-grade Glioma","High Grade Glioma",[120,121],"Prospective study","Patient-derived organoids","2026-01-26",{"date":124,"type":28},"2026-01-27",{"date":126,"type":28},"2022-05-01",{"date":128,"type":19},"2028-12",{"name":34,"class":35},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":36},"100411511","preselection-of-patients-at-risk-for-cognitive-decline-after-radiotherapy-using-advanced-mri-100411511","NCT04638478","PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI","Inclusion Criteria:\n\n* Meningioma WHO I, grading based on pathology or radiological features\n* Age ≥ 18 years.\n* Karnofsky Performance Score 70 or above.\n* Ability to comply with the protocol, including neuropsychological testing and imaging.\n* Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Resection meningioma \\\u003C 3mnd\n* Age \\\u003C 18 years\n* Pregnancy\n* Any prior cranial radiotherapy\n* Any prior chemotherapy in the last 5 years\n* Contra-indication for MR imaging (i.e. metal implants, claustrophobia)\n* Any other serious medical condition that could interfere with follow-up.\n* Severe aphasia or language barrier interfering with assessing endpoints (i.e. completion of questionnaires or neurocognitive performance)",{"count":137,"type":19},67,"Meningioma are slow growing and frequently occurring intracranial tumors, responsible for 33% of all asymptomatic intracranial tumors and 13-26% of all symptomatic primary brain tumors. The 10-year survival rate is 72%. A variety of treatment options is available for symptomatic meningioma including surgical removal with or without radiotherapy or radiotherapy alone. These therapies can have negative impact on cerebral functioning.\n\nAfter high dose radiotherapy for primary or metastatic brain tumors 50-90% of \\> 6 months' survivors develop irreversible disabling cognitive decline leading to premature loss of independence, reduced Quality of Life (QOL) as well as significant economic burden both at the individual as societal level. Especially for patients with a good prognosis like benign meningioma, maintaining neurocognitive function is crucial. Understanding the mechanisms underlying radiation induced cognitive decline is complex and which brain areas to spare are an important subject of research.\n\nEvaluation methods to assess cognitive function and predict cognitive decline are urgently needed, this will allow the development of optimized treatment strategies with the aim to preserve or even improve cognitive function in meningioma patients. Improvements in the field of neuroimaging techniques (i.e. advanced MRI techniques) have the possibility to identify areas susceptible to cognitive impairment. This allows in the future a more personalized radiation treatment by identifying patients at risk, by optimizing the radiotherapy dose to specific brain regions, that could eventually reduce or prevent, cognitive decline. Improvements in the field of radiotherapy for example by higher precision treatment such proton therapy have potential in obtaining these more individualized strategies.",[140],"Meningioma",[140,142,143,144],"Radiotherapy","MRI","Neurocognition","2025-09-23",{"date":147,"type":28},"2025-09-29",{"date":149,"type":28},"2021-04-08",{"date":151,"type":19},"2029-05-01",{"name":34,"class":35},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":20,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":36},"100208117","outcome-prediction-in-headneck-cancer-patients-after-radiotherapy-100208117","NCT01985984","Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy","Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Using Multi-parameter Modelling: Disease Control, Toxicity and Quality of Life","OutcomeH&N","Inclusion Criteria:\n\nAll patients planned for curatively intended primary or postoperative radiotherapy\n\nExclusion Criteria:\n\nAll patients planned for palliative radiotherapy",{"count":162,"type":19},1000,"5 Years","The primary and general objective of the clinical introduction of the Standard Follow-up Program (SFP) as the current standard of care is to improve the quality of radiotherapy for head and neck cancer patients by reducing radiation-induced side effects without hampering treatment efficacy in terms of locoregional tumour control and overall survival and to systematically evaluate the beneficial effect of newly introduced radiation technology for this particular group of patients. The clinical introduction of the SFP will allow for a systematic and broad scale quality improvement cycle for head and neck cancer patients treated with radiotherapy. In fact, this methodology can be considered a kind of quality circle for the clinical introduction of new radiation techniques, aiming at continuous efforts for further improvement.",[166],"Head and Neck Cancer",[168],"Head and neck cancer","2025-08-11",{"date":171,"type":28},"2025-08-14",{"date":173,"type":4},"2012-07",{"date":175,"type":19},"2030-01",{"name":34,"class":35},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":80},"100433728","detect-target-volume-for-rectal-endoluminal-radiation-boosting-100433728","NCT04927897","DETECT: Target Volume for Rectal Endoluminal Radiation Boosting","DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer","DETECT","Inclusion Criteria:\n\n* ≥18 years of age and capable of giving informed consent.\n* ycT1-3N0(\\*) residual(\\*\\*) histology confirmed rectal adenocarcinoma after neoadjuvant radiotherapy or long-course chemoradiotherapy for which patients will undergo TME surgery.\n* Minimal interval between end of neoadjuvant chemoradiotherapy or radiotherapy: 6 weeks.\n\n(\\*)= as determined by clinical assessment (digital rectal examination, endoscopy with or without biopsy) and\u002For MRI. Biopsy\u002Fhistology around the time of diagnosis is adequate; no biopsy\u002Fhistology is needed after neoadjuvant therapy.\n\n(\\*\\*)= including tumor regrowths\u002Flocal recurrence after an initial clinical complete response and a \"watch and wait\" approach. These patients will also be included after the local recurrence has been determined using endoscopy and\u002For MRI.\n\nExclusion Criteria:\n\n* Patient has received brachytherapy as part of neoadjuvant treatment.\n* \\\u003C18 years of age or incapable of giving informed consent.\n* Patient has not been treated with neoadjuvant radiotherapy or long-course chemoradiotherapy.\n* Patient will not undergo TME surgery for a ycT1-3N0 residual histology confirmed rectal adenocarcinoma.\n* Interval between end of neoadjuvant therapy and surgery is \\\u003C6 weeks.",{"count":114,"type":19},"The aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.",[93],[93,189,190,191],"Microscopic Tumor Spread","Target Volume Definition","Endoluminal Radiation Boosting","2025-07-24",{"date":194,"type":28},"2025-07-28",{"date":196,"type":28},"2022-08-16",{"date":198,"type":19},"2027-12",{"name":34,"class":35},{"id":201,"slug":4,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":80},"100446328","NCT05092009","Lung Cancer Organoids and Patient Derived Tumor Xenografts","IPON-3","Inclusion Criteria:\n\n* All patients selected to undergo primary surgical resection of a primary lung cancer. All types of resection are eligible, e.g. wedge resection, segmental resection, lobectomy, pneumonectomy.\n* All patients with (suspected) lung cancer that will undergo a bronchoscopy or endobronchial ultrasound guided transbronchial needle aspiration (EBUS\u002FEUS-TBNA) bronchoscopy.\n\nExclusion Criteria:\n\nThere are no exclusion criteria",{"count":47,"type":19},"Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn. From this material the investigator will try to establish matched normal and primary human lung cancer organoids.",[209],"Lung Cancer","2025-07-14",{"date":212,"type":28},"2025-07-15",{"date":214,"type":28},"2022-10-05",{"date":216,"type":19},"2028-04-01",{"name":34,"class":35},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":36},"100139358","biobank-carcinoma-storing-blood-and-protein-of-patients-with-cancer-100139358","NCT01084785","Biobank Carcinoma: Storing Blood and Protein of Patients With Cancer","Storing Blood for Analysis of DNA and Protein of Patients With Cancer in MAASTRO Clinic","Biobank","Inclusion Criteria:\n\n* cancer\n\nExclusion Criteria:\n\n* not able to comply with follow-up",{"count":227,"type":19},10000,"The purpose of this study is to determine, by means of DNA and protein analysis, the relationship between DNA and protein profiles and a number of endpoints, which are important for the patient such as overall survival and side effects.",[230],"Cancer",[230,232,233],"genomics","proteomics","2025-05-08",{"date":236,"type":28},"2025-05-13",{"date":238,"type":4},"2003-01-01",{"date":240,"type":19},"2026-05-01",{"name":34,"class":35},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":88,"minAge":4,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":36},"100534571","in-vivo-treatment-verification-of-brachytherapy-100534571","NCT06240559","In Vivo Treatment Verification of Brachytherapy","In-vivo Treatment Verification for HDR Brachytherapy Patients Using an External Imaging Panel","Inclusion Criteria:\n\n* Treatment site Gynaecology (Endometrium\u002FCervix) and prostate\n* Treatment: HDR Brachytherapy\n* Patient will be treated on CT Couch\n* Mentally competent patient\n\nExclusion Criteria:\n\n* Incapacitated patient",{"count":250,"type":19},100,"To acquire data during High Dose Rate (HDR) brachytherapy treatments aiming to track the brachytherapy source inside the patient verifying the delivery of the treatment plan.\n\nMedical images (CT,MRI and US) combined with software developed by the investigator will be employed to predict the response of the Investigational product during the treatment and will be used as reference.The IP will be placed on the side of the treatment table and will acquire data during the whole treatment, which will be compared against information derived from the treatment plan. The IP based method can detect errors and information about motion and treatment uncertainties that are not currently available.",[253],"Brachytherapy","2025-05-06",{"date":256,"type":28},"2025-05-09",{"date":258,"type":28},"2024-02-29",{"date":260,"type":19},"2026-02",{"name":34,"class":35},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":88,"minAge":16,"maxAge":4,"enrollmentInfo":268,"targetDuration":163,"studyType":20,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":80},"100412277","proton-therapy-research-infrastructure--protrait--neuro-oncology-100412277","NCT04648462","Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology","Inclusion Criteria:\n\n1. All brain tumors with a favorable prognosis (median survival \\> 10 year)\n2. Age ≥ 18 years\n3. ECOG performance status 0 - 1 \u002F Karnofsky performance status 80 - 100\n4. No - minimal neurocognitive impairment\n5. Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial brain dose or hippocampi)\n6. Informed consent\n\nExclusion Criteria:\n\n1. Not eligible for chemotherapy\n2. Eligible for stereotactic radiotherapy",{"count":269,"type":19},1500,"The first proton therapy treatments in the Netherlands have taken place in 2018. Due to the physical properties of protons, proton therapy has tremendous potential to reduce the radiation dose to the healthy, tumour-surrounding tissues. In turn, this leads to less radiation-induced complications, and a decrease in the formation of secondary tumours. The Netherlands has spearheaded the development of the model-based approach (MBA) for the selection of patients for proton therapy when applied to prevent radiation-induced complications. In MBA, a pre-treatment in-silico planning study is done, comparing proton and photon treatment plans in each individual patient, to determine (1) whether there is a significant difference in dose in the relevant organs at risk (ΔDose), and (2) whether this dose difference translates into an expected clinical benefit in terms of NormalTissue Complication Probabilities (ΔNTCP). To translate ΔDose into ΔNTCP, NTCP-models are used, which are prediction models describing the relation between dose parameters and the likelihood of radiation-induced complications. The Dutch Society for Radiotherapy and Oncology (NVRO) setup the selection criteria for proton therapy in 2015, taking into account toxicity and NTCP. However, NTCP-models can be affected by changes in the irradiation technique. Therefore, it is paramount to continuously update and validate these NTCP-models in subsequent patient cohorts treated with new techniques. In ProTRAIT, a Findable, Accessible, Interoperable and Reusable (FAIR)data infrastructure for both clinical and 3D image and 3D dose information has been developed and deployed for proton therapy in the Netherlands. It allows for a prospective, standardized, multi-centric data from all Dutch proton and a representative group of photon therapy patients.",[272,273,274,275,276,140,277,278,279,280,281,282],"Astrocytoma","Ependymoma","Ganglioglioma","Oligodendroglioma","Optic Nerve Glioma","Nerve Sheath Neoplasms","Adenoma","Craniopharyngioma","Hemangiopericytoma","Germinoma","Neurilemmoma","2024-11-25",{"date":285,"type":28},"2024-11-26",{"date":287,"type":28},"2018-01-01",{"date":289,"type":19},"2035-01-01",{"name":34,"class":35},""]